>> amgen, a for amgen. >> nice. >> see what you did. >> i'm melissa lee, >>> hey, i am kramer and welcome to mad money. going to make friends and i am just trying to make you some money. my job is to coach and teach you, so call me or tweet me at jim kramer. sometimes we have to remove all emotions from the equation when you try to analyze and look at a stock, you can not say

amgen shares are higher after the earnings report.r linked in, it hasn't been a good week for social media. should investors be getting social anxiety? you're watching cnbc first in business world wide. can it make a dentist appointment when my teeth are ready? ♪ can it tell the doctor how long you have to wear this thing? ♪ can it tell the flight attendant to please not wake me this time? ♪ the answer is yes, it can. so, the question your customers are really asking is, can your business deliver? but with all this speed from xfinity, it's all good. hey, why don't we do some homework for a change? gary, you too. dad...work stuff. yes! [laughs] lovin' the new design! konichiwa hirosan. five minutes... all this speed is very empowering. check out the new hardware. with the fastest, most reliable in-home wifi, xfinity is perfect for people who need to get a lot done at home. my name is jamir dixon and i'm a locafor pg&e.rk fieldman most people in the community recognize the blue trucks as pg&e. my truck is something new... it's an 811 tr

. >>> amgen's profits up. amgen is expecting fda approve of what could be the next big drug, a new cles ralholesterol fighter. up 0.9%. >>> electronic arts first quarter revenue and profits beat numbers. it gears up for one of the most an pateanticipated games of the year, star wars battle front. i know carolin is looking forward to it. >> not so much. not as much as you with. >> ea's outlook disappointed analysts analysts. shares fell about 3% in afterhours trades. >>> linkedin reports a wider second quarter net loss than expektded. related to acquisitions and expanding the sales team. a 33% rise if revenues was driven by strong growth and the recruiting business. it's raising the guidance. that was much less than analysts forecast. shares fell 3% in afterhour tradesing. >>> on that note with facebook amazon netflix, and google, with youare you buying the fang? join in on the conversation. get in touch by e-mail. tweet us at cnbcwex. which one are you buying or selling? >>> still to come on the show dark time

i think you get to buy amgen no, questions asked, at these levels. news came out on celgene, basically scared people in amgen and i'm telling you right now at the stock -- i think 158's where the stock went out. it's a close your eyes buy amgen level. >> to me i'm not sure -- yeah. biotech i'm not sure there ever is a close your eyes and buy. in this type environment. certainly a month ago, certainly six months agoes that's what people were doing. but for the same reason i was raise soing some cash in other s of the portfolio i think it's a no touch here. i realize a lot of the other bellwethers are with a pullback. valuation could be justified. it's just not me here. >> one point to add, though, i think biogen although it could scare people what it could set up is who are they going to buy? they have a growth issue. they're going to have to go out and make an acquisition. they could actually start to buy some companies. that's the interesting play here. >> so could gilead. gilead's reporting next week. gilead got scared because of abby's earnings. >

i don't think there's any way anybody buys amgen. premium on their market cap makes that $135 billion deal. i don't think there's any shot of that happening. that said i think amgen should have gone up regardless of this. i think valuationwise it makes sense for a lot of different reasons. >> and the valuations are going higher and the deal prices are going higher as well we should note. thank you, meg. our resident therapist meg tirrell. up next will the carnage in china continue? we're counting you down to the open in asia and taking you live to hong kong right after the break. >>> plus, social media's moment of truth. twitter out with earnings tomorrow after the bell, and we've got the three key metrics you need to watch ahead of that big report. it's your earnings edge. "fast money" style. straight ahead. ness expert from at&t? yeah, give me a problem and i've got the solution. well, we have 30 years of customer records. our cloud can keep them safe and accessible anywhere. my drivers don't have time to fill out forms. tablets. k

good news for amgen. they have a couple of blockbusters in the pipeline. it is all about tomorrow for these stocks. melissa, back to you. ashley: lori has the linkedin numbers. find out how they reported, lori. >> looks pretty good for linkedin, job search website. 55 cents versus 51. beat on bottom line. top line strong as well. versus expectations of 680.08 million. i want to look at ad sales breakdown. linkedin shares were down 3%. after-the-bell earnings call. we will see if there is a reaction. that will tell us a lot about what investors keying into, linkedin, unlike twitter and facebook doesn't have access and main revenue drivers are not necessarily ad sales for linkedin. more about recruiting tools and resource products and premium is description. i will be back throughout the hour to give you more details. >> thank you, lori, so much. i want to correct one thing, looked like earnings per share was 55 cents. the estimate was 51 cents, right? ashley: the estimate was for 30 cents. melissa: she said 51. estimate was for 30 cents. ashley: get reactio

you look at the celgenes, the gileads, the amgens, the biogens, they're all going to stay at these levels and probably continue to move higher. >> so not a problem for health care at all. >> it's not a problem for the larger safer names. again, bottom of the barrel just like in energy it's an issue. very big issue for them. >> i tell you what. i kind of agree with what i think guy is saying. the pain trade could be higher even though the volatility seems to be up there. i would actually argue the volatility has crept its way in. we had a couple moments here where we were at 16 on the vix. that really is the level. yet two or three days, 13%, 14% vol moves. but if you think about thematically, investors are very thematic right now and health care and biotech, nothing is changing. the demographics in this country tell you that health care is going to be a very important part and the hospital stocks continue to move and the consolidation. i think when you look at oil and you look at commodities specifically it's easy to argue that there are sector-specific things going on. i know people want

>> amgen, a for amgen. >> nice. >> see what you did. >> i'm melissa lee, >>> hey, i am kramer and welcome to mad money. going to make friends and i am just trying to make you some money. my job is to coach and teach you, so call me or tweet me at jim kramer. sometimes we have to remove all emotions from the equation when you try to analyze and look at a stock, you can not say how can it go down like that. i have to buy it. maybe i should sell it. what you have to do is use key metrics. kill sets and cold hard facts. hast that's how they arrive -- when you see an american icon leading the dow jones down for the day you can not be shocked or perplexed. you have to be cloin cal and skeltd balance. i mentioned that -- it's not out performing them now and it's stocks should not either. whether it's lacking kilg er innovation or maybe it's too large to manage or simply because it's charging too much and they're hitting you up for the packaging. let's just own the fact that at the end of the day proctor's not de de delivering by what matters. in any business there are key yardsticks to follow an

>> celgene, regeneron, and amgen.o, you know -- well, it's a long -- what was she doing talking about valuations of stocks anyway? is that something new? >> fed policy. i'm sure she thinks -- she's delighted with your opinion on -- >> i don't know if you can make that comparison. she has no business. none them have any business talking about stocks, period. seriously. that's not their bailiwick. not that we have a bailiwick here. but it's certainly not theirs. >> a wick. >> you shouldn't be worried about asset bubbles. they help create them. so they should be worried about them. here's a situation where meg just said celgene's trading up 5% in the after hours. that's a little more than halftime purchase price of reseptos or whatever they are who has no sales and is going to add some sales diversification to celgene in 2019. it's kind of fairy dust here, people. that's where we are right now with some of is this stuff. so if the fed chair is worried about asset bubbles building, this is a $7 billion acquisition. >> she

finally, we want to talk about amgen.nd lower operating expenses let it to not only be but raise its revenue and earnings forecast for the year. alix: so what you miss in today's gdp announcement? michael mckee is with us to tell us about it. michael: feel like you are doing more and accomplishing less estuary the numbers seem to suggest that is the case. the government re-benchmark the gdp numbers and growth was lower over the time, which means productivity was lower because we the number of workers increase and unemployment go down, so more people were actually accomplishing less, and that has some implications for the market and the fed. dsa -- be available to how we could reconcile this could reconcile the difference between employment and economic growth, but now it seems like the puzzle is more extreme. michael: we are recognizing it in that it should have higher. we're not in companies that money into the kind of enhancing investment at least two and we saw decline in business investment in the most recent order, s

. >> bernstein analyst says abvee, amgen and bioagain may be on the list. each has a market valuation of $70 billion. allergen sls to a bigger company like pfizer which was unsuccessful last year in its more than $120 billion bid to bias electra zeneca. where does this leave mylan, no longer a target for teva. it only intensifies to buy rival parago a deal that so far parago has rebuffed. the consolidation frenzy is a rise rising health of costs. drug companies in turn must buy in order to get a bigger piece of the pie. for nightly business report i'm meg terrell. >>> a record find for phi at/chrysler over mishandling safety recalls. it's part of a settlement which has been highly critical of how the automaker handled defects. that pressured the stock which fell nearly 5%. the agreement comes just days after chrysler recalled more than a million cars to block hackers from taking control of the vehicles. will that recall impact sales? phil lebeau has the surprising answer. >> it's a whopper of a penalty for fee at chrysler the auto maker will pay $105 millio

that is when she was recommended a drug from amgen.it's injected into the tumor, and uses a genetically modified version of the herpes virus to break down the cells. >> it would target to the tumor cells, and not go to the normal cells. >> fewer than 20% of the patients experience the full benefit, she says the drug showed ability to shrink both injected tumors and satellite tumors with multiple tumors on her foot, her odds of survival were less than 5050. >> we injected both of those tumors every two weeks and over that period, they gradually went away. and they went away completely. >> the doctor believes it may be combined with other newly emerging drugs to enhance the affect. in the meantime, laurie is back running her retail stores, cancer free for five years. >> did this drug save my life? i would say yes. >> the full fda must make the decision. >> coming up, good and b it's tougher than ever to be a... ... foster farms chicken. but foster farms simply raised chicken... ... is 100 percent natural... ... with no antibiotics. gasp!

that is when she was recommended a drug from amgen.s it's injected into the tumor, and uses a genetically modified version of the herpes virus to break down the cells. >> it would target to the tumor cells, and not go to the normal cells. >> fewer than 20% of the patients experience the full benefit, she says the drug showed ability to shrink both injected tumors and satellite tumors with multiple tumors on her foot, her odds of survival were less than 5050. >> we injected both of those tumors every two weeks and over that period, they gradually went away. and they went away completely. >> the doctor believes it may be combined with other newly emerging drugs to enhance the affect. in the meantime, laurie is back running her retail stores, cancer free for five years. >> did this drug save my life? i would say yes. >> the full fda must make the decision. >> coming up, good and female announcer: get three years interest-free financing on brand name mattress sets. plus, get free delivery, and sleep train's 100-day low price guarantee. sle

names, google, apple, microsoft make up a disproportionate, but you also have sell jean and biogen and amgen and we have one down 20%. it's round trip, the entire move of the last 52 weeks, and now it's down 37% from the 52% high in march and that's horrible reaction. what i'm saying, a lot of other stocks are cheap and defensive and technically look and feel okay but if you lose this part of the bull market you're losing a massive group of leadership, okay, so when you think about technology on flip side, okay, we know that apple has been range-bound and may remain range-bound. i don't think the gamins in aal and google are very constructive. facebook is coming and let's see how that responds. that stock up 15% speaks to narrow is breadth and speaks to people really trying to concentrate and figuring out where they can high. >> meg mentioned exeli exelisis people are having a hard time figuring out where these are valuinged and if people decide to go the other way it can move down just as quickly as it moved up, maybe even more so. >> i want to ask more about the qs. >> the qqq, up 50% of t

disproportionate amount of the weight but you also have a gilead, you have celgene, biogen and you have amgen today you have one of these we just mentioned before was down 20%. closed on the dead low, people. its round trip the entire move of this last 52 weeks and now it's down 37% from the 52-week highs in march. that is horrible action. just to kind of reiterate what i'm saying is a lot of the other stocks yes, they're cheap, they're defensive and technically they look and feel okay but if you lose this part of the bull market you're losing a massive group of leadership. so when you think about technology on the flip side of it we know that apple's been range bound and may remain rangebound. i don't think the gains in amazon and google in the last week are very constructive. while facebook's coming and let's see how that responds. but i don't think that seeing stocks of that magnitude up 15% breaking out to all-time highs, that speaks to narrowing breadth to me. it speaks to people really trying to concentrate and figure out just where they can hide. >> it's interesting that meg mentioned

looking at my sheet here -- amgen and eli lilly are migraine cure.we know pricing for it or what it would entail? guest: we have no idea of prices because it is too early. it looks like a pretty serious treatment and not something you take just because you get an occasional headache. have to have to injections and it's basically a prescription drug, not a pill, and not something you could get over-the-counter. at least not yet. thank you so much. you could always get a botox. .etty: not you one could do that. i have a picture for you, scarlet. scarlet: we do not reveal secrets here. remember i showed you this picture of my morning commute, which took forever. i come in from new jersey and it .ook me an hour and 45 minutes is it because we see so many cars on the road because of uber? i noticed this -- it was just right around the corner -- tons of yellow cabs around me. three or four of them were empty at the rush hour. so might bill de blasio be right? uber is not only taking away business from the taxicabs, which we know for sure, but they are caus

amgen being the target.ng one but that's helping health care higher in today's market. >>> a painful month for china's stock market. all seeing sharp declines in july. are there opportunities to be found or is investing in china still too risky? john rutledge is a cnbc distributor. always great to see you. >> nice to see you. how you doing? >> great. great. the consensus, john is that the stock market and the chinese economy are different but we are seeing aren't we the knock-on effects of the slowdown in the chinese economy in the commodities market. why wouldn't we see the slowdown in other parts of the market? >> parts of the chinese mark are very sensitive to commodity prices which is oil and commodity sectors. but banks, life insurance companies and the like the rest of the companies that make up the big caps are really not so price sensitive and falling prices are good for incomes in china, too. china is slowing. it is going to continue slowing but it is not collapsing. but the market and the economy a

. >> i'll stick with amgen. real quick, i love this name but the reaction out many of these names has not been as strong as anybody expects. on any pullback i'd be a buyer. >>> "power lunch" begins right now. >> announcer: "halftime" is over and the second half of the trading day starts right now. >>> thank you very much. along with mandy drury, i'm tyler mathisen. beyond the markets we hit key three things today, all with a major impact on you. >>> topic number one impacts the way that we drive. new crash tests are out that show the potential downside of recent engineering changes to one of the most popular vehicles on the road. >>> then there is the question of how and where we live. new numbers show something big is changing pricing in the housing market. >> yeah. absolutely. then there is the way that we invest. exactly we're watching what's been happening with gdp and what that means of course for the fed and for your money. >>> we got three reporters covering it all there. phil lebeau on the cars and the c

amgen is the first in the world but regeneron could be first in the united states. how broad and much will it cost. >> how much -- that's hard to answer but we're looking at a stock up 35%. >> regeneron is remarkable. ever core initiated saying it could be the best biotech company on the planet and initiated with the hold because evaluation has gone up. a lot of this, expectation is priced in here. a slow lunch getting reimbur reimburseme reimbursement? it really does help lower the risk of heart attacks and strokes or recoup the investment. >> have to let you go. meg terrell, stock therapist, guy? >> reagain ron, the stock is ballistic. a $300 stock, 560 now and trades close to 41 times forward earnings. one would have to think the good news is priced into this name. so probably makes sense if you enjoy the ride to take money off the table. i'm not one to pull the rip cord on biotech but you might have to. understanding that, if everything comes out favorable, they have earnings in a week and a half two weeks, it could continue higher. at these levels, you have to

the fda is scheduled to rule on a similar drug from amgen by the end of august. expected to launch its own on the try into the category as early as 201. 2018. >>> would you be willing to pick up packages from amazon? people in sunnyvale may have the option. the silicon valley business judge reports the e-commerce giant plans to build its first drive through grocery store there. a developer has submitted plans for the site at the orchard supply center. customers would order online and then schedule a pickup. but will people actually buy into the new concept? >> just the fact that it's amazon and they are much more effective at getting you a product efficiently than some of the other companies might be enough for people to give it a try. >> reporter: amazon is not confirming anything. neither is the city. but the business journal reports if the concept works amazon could ee have beenly roll out -- eventually roll out more stores in the area. >>> two of the biggest sports teams in the world are in the bay area right now. they play tomorrow. we'll take a look tonight

am again, biotech company -- amgen. electronic arts also strong. electronic arts had strong quarter considering that the spring quarter for the videogame company is weakest quarter. holiday quarter is where they put all their ducks. fireeye, cybersecurity company also had a solid quarter. that company has grown 48% year-to-date. back to you. deirdre: lori rothman joining me from the floor of new york stock exchange. you heard lori talked about linkedin. it is moving post-market. beating earnings projections on the top and bottom line. chief market analyst with me from wealth empire, ross givens. ross, first and foremost, what is your take? from my take looks like a blowout quarter. stock is moving lower in the post-market though. >> deirdre, i couldn't agree more. excited about linkedin. 33% beat on revenue is huge. i think everyone is missing big story here on linked in. everyone is focused on profits. analysts anticipating 30 cents a share. put up 40, 45 cents. talking about a 225-dollar stock. nickel or dime one way or the other wouldn't make a

. >> but amgen was up 5%. one of the biggest names on takeover spec. it seems a bit frothy here. i know you guys talk about valuation and you talk about a company that has 90% market share in hep c as gilead has here. but if you look at consensus estimates for next year for earnings and sales, they're basically flat. so you have a stock trading ten times that. and this is a defensive sector. we get it. they're very cyclical based on these product cycles. we know this is a stock that sold off 20% in december when all of those fears about pricing were around. so to me i know it bounced off 100 last year and went straight to 120. here you are in the mid-point here. you're going to have the stock butting up against 120 again. i don't think you play it for a breakout right here. >> i do disagree because it's so shareholder friendly, when you look at them they've shrunk the share count 7% in the last five years. now you have 10 billion. they're going to shrink it even more over time. when you look at the growth -- and, by the way the hep c, now that they're approved in japan as well th

. >> i'll stick with amgen.k, i love this name, but the reaction out many of these names has not been as strong as anybody expects. on any pullback, i'd be a buyer. >>> "power lunch" begins right now. >> announcer: "halftime" is over and the second half of the trading day starts right now. >>> thank you very much. along with mandy drury, i'm tyler mathisen. beyond the markets we hit key three things today, all with a major impact on you. >>> topic number one impacts the way that we drive. new crash tests are out that show the potential downside of recent engineering changes to one of the most popular vehicles on the road. >>> then there is the question of how and where we live. new numbers show something big is changing pricing in the housing market. >> yeah. absolutely. then there is the way that we invest. exactly we're watching what's been happening with gdp and what that means of course for the fed and for your money.

amgen, big gain for a very big company. >>> look at this. facebook's new drone.ot that one. there is a much bigger one, much bigger one out there. it's a huge thing. it is the size of a boeing -- >> 73. stuart: 47? >> 37. stuart: it's big. they plan to fly this thing in circles, all around, basically underpopulated areas. >> doesn't even need an engine. stuart: that is in the factory. that is the thing in the factory. just building this thing getting it together. they want to fly it around in circles. so you can beam down internet to those who currently can't get it. standing in the middle of the sahara, take your pick and have access to the facebook profile this thing goes around. already most widely used tech product. this could help them expand further. the stock is done a little, no up a buck now. they're watching the show, i can tell. closing in on 100 buck as share, we think. we shall see. now this. there is a company that is part of the on demand economy. it is called lux valet. they are making major change. by the way they park your car for you. big chang

>> in , maybe sooner there could be a similar drug from amgen, pfizer has their own drug that is a couplears out. they are enough like each other that insurers are going why are we going to have to pay such skyhigh prices, we will put you against each other and go with whatever the lowest ice we can get as they will do the same thing they just did and hepatitis the, with some of those super expensive medicines. matt: do any of them have drugs that make sense or will sell? lipitor and viagra are successful. >> pfizer does not have a brand name just yet, but it is crazy names. fda approves all of these names and you did something that is going to be a global brand we do not want it be donkey in spanish or something like that. you cannot sound like something you would market with. you cannot say take hamburger away and eat as many sticks as you like. matt: one of the things that is the issue is the cost. these the kind of drugs that you take for the rest of your life. >> these are injections that you will take either every two or four weeks or something like that. they will cost thousands of

today we've seen amgen, expedia, good earnings, lead to higher stock prices, for every one that's gone down, you might find one that's gone up and might be why the market-- >> what do you tell people as the average finish off as they began? in the middle of that, crazy. >> you know, this is not the first month this year we've seen that. in fact, you might say the whole year has been that way. when the market is essentially unchanged, up an skosh, if you will. and china, growth uncertainties, that's the stock market. you've got to have a long-term time horizon, it's the in between fluctuation that gives you too much tense sleep at night or whatever your issues are, you're in the wrong place, or don't listen to me talk, just invest and hold for the long-term. >> do you look at the interest rate hike to come as the sell off of the market or it's so widely anticipated that it won't be a big deal? >> because it's zero to 1/4 of 1%, we're making much ado about nothing. i think when the fed raises rates it's actually some verification, some agreement that the economy is doing a bit better. we

they can buy amgen if they want to. don't forget they have a great tax basis because they're a foreign country. >> saunders talked about future deals. >> that's right. >> that great tax status. brent, i know the company is braced overseas. he is based about 25 minutes from me in jersey. that's over the hudson. but i like the deal so much for allergan. they are able to control their own destiny it is the great growth stock in that group. be i the way the proprietary drugs are fantastic t. stock was up 36 at one point this morning. because it's a member of the s&p it's come down. >> is it the same school of thought as all sper gan on friday? should people be that worried of a spa is? >> they talked themselves up big about this alzheimer's drug which is good it's four years away. the numbers were miserable. they guided it down. you have to think about what your end stage sales are going to be much much lower. they didn't get this stroke yield didn't work. so it was a triple wammy. the stroke drug is not going to be able to

. >> celgene, amgen, gilead these are different biotechs. >> they dominate that index.'s easy to lump all these names together. gilead celgene, biogen these are different animals than some of the names that soar 40%, 50% on earnings or takeout rumors. >> twitter's quarterly results are out. let's get straight to those with julia boorstin. >> twitter beating on the top and bottom line reporting adjusted earnings 7 cents per share, 3 cents better than wall street projected. revenue higher $502 million versus $481 million estimated. the company reporting 316 monthly active users. that's 6 million more than projected. wall street had been looking for 310 million. last quarter it was 302 million. this is slightly better be expected for that all-important active user number but not a dramatic increase as we've seen with facebook in terms of their number. we'll be back with more. >> thank you so much. >> we are not going to show you the share price action for twirt in the session. it is up 11% after hours earnings. a big pop for the name. beaten down into this report. >> this

. >> one analyst was picking names like amgen, biogen as potential targets. and he talked to sam eisley act actavis could be shrinking itself to be bought. >> how much consolidation and concentration are we seeing in this industry? what effect will that have on prices people are paying for these drugs? >> one side people say consolidation we are seeing among insurers is driving this consolidation among drug companies to keep the power balance. insurers are pushing back on high costs of drugs. they are getting together to push back on that. folks say perrigo will be in play no matter what whether it goes to mylan or tries to sell itself to somebody else. people are starting to get worried about what that means for anti-trust in terms of all the drug companies. >> wonder if as sam eisley said he expects mylan to raise the bid for perrigo. >> it's coming under pressure. >> perrigo is saying no go. we are not interested correct? >> absolutely. folks are telling me maybe if the perrigo deal doesn't happen perrigo will look for another buyer. >> the drama will cont

amgen not moving as much. esperion they make another cholesterol drug that would be taken orally.olks think that benefits from this broader label. >> thank you. before 2000 the average cost of a cancer drug for a year of therapy ranged between $5 and $10,000. 2012 the cost increased to more than $100,000. >> over the same period the average household income in the united states decreased by about 8%. these rising costs causing an uproar in the medical community as a group of doctors from the mayo clinic ban together to try and lower costs for patients. joining us for more discussion of this is a hematologist at the mayo clinic. welcome. good to have you with us. of all the things you have proposed by way of trying to get control of rising drug costs, which one would have the greatest effect? would it be preventing the companies from banding together to delay generics having medicare be able to negotiate the prices with the drug manufacturers? which would be the single best or most important one? >> i think in my opinion the single most important one and the one that can be immedia

. >> besides just the pharmas, talk about the big biotech stocks gilead amgen, biogen.es of stocks. roches. they're the stocks seen driving a lot of the action. it might be that they have a pipeline, not just a lot of profits. we could see some of the pipeline results play out further down the line. next hour on "power lunch" we'll take a look at some of the best performing small cap stocks out there. guess what industry many of them are in? >> biotech. >> there you go. >>> perfect way so seg to the next segment, guys. our market guests mark you are very bullish on biotechs. i'm sure you just heard that conversation about concerns about bubblish behavior. do you want to push back on that? >> we've been having this conversation for the last two or three years. while that two or three years has happened we've had a myriad of successes from the fda on new drugs. a myriad of m&a activity. i don't see that changing. very interesting fashion the acquire er acquirer, the stock is up 10%. the kind of drugs that are out there are the kind of shots on goal the biotechs are gettin

you had a note out earlier about amgen. are people underestimating the power they have there?lissa. we think people are generally underestimating the earnings power of almost all of the larger profitable biotech stocks. especially in a marketplace where just a lot of other sectors are not performing. we've had our share of misses early on in this earnings cycle but the big cap biotechs are benefiting from an older population benefiting from obamacare and more coverage for more people. they're certainly benefiting from aggressive u.s. pricing environment as well. >> all right, eric schmidt, a pleasure. thank you. >>> we get a news alert now. over to mary thompson. >> the new york department of financial services is asking for information on symphony. you might recall that is an instant messaging system that's been opbasically backed by a number of big banks including goldman sachs. the dfs wants to know how symphony plans to retain certain documents and messages within that system because regulators are concerned how they may have to access some of this information in the futur

amgen ahead of its earnings next week. perrigo up. that mylan is going to continue to per sue perri go o in that biotech game. also some big caps that are doing well today, american airlines even as the airline index is off 3% is up after posting better than expected earnings. as usual, the usual suspects amazon and google are up on a day when the rest of the market is down. >> bertha thank you. >>> china and europe roiling the markets today. uncertainty overseas causing a lot of anxiety for traders and maybe even for you. but how will it affect the fed which is meeting this week? let's bring in senior economics reporter steve leisman. steve? what say you? >> i think it is a big factor. i think the factors that are out there now. so they pretty much have -- are where they want to be on jobs and job growth. that's one. the big factor outstanding on domestic is the inflation level. then the third factor i would say, determining whether or not they hike rates is what happens globally overseas. i want to give you a little heads-up. folks,

amgen, a bullish note out of cowan recently raising prices on a number of their drugs.ying it underestimates the prices and stock is flat though on a call. >> the stock is up 36% over the past year. >> yeah. >> its market cap is now 124 billion? that makes it bigger than bristol meyers and eli lilly. i think we need to change our definition in the media what big pharma is. >> big biotech. >> crisp stock, and anna core 6.5 million market cap, working on an anti-fungal product. goldman sachs upgrading it to a buy from neutral. the target. i know you're going to flip out on this one. target was bumped to 195 from 60. >> way behind. >> are you flinching from me because you think i'm going to strike you? >> general flagellation. the stock is at 151, so take this call with a grain of salt. the analysts missed. >> much of the upside. >> i debated internally and put this in the under radar. >> a good one though. >> if an analyst leaked and issued a mea culpa. >> is that what the analyst said? >> rarely you get that and you get analyst speak because 100 lawyers have to go throug

. >> and also amgen is making almost an identical version.t think a big city is the place for a winery, but some folk in seattle are here to show you what you never thought was possible. it is not the device that is mobile it is you. i'm only in my 60's. i've got a nice long life ahead. big plans. so when i found out medicare doesn't pay all my medical expenses, i looked at my options. then i got a medicare supplement insurance plan. [ male announcer ] if you're eligible for medicare, you may know it only covers about 80% of your part b medical expenses. the rest is up to you. call now and find out about an aarp medicare supplement insurance plan, insured by unitedhealthcare insurance company. like all standardized medicare supplement insurance plans it helps pick up some of what medicare doesn't pay. and could save you in out-of-pocket medical costs. to me, relationships matter. i've been with my doctor for 12 years. now i know i'll be able to stick with him. [ male announcer ] with these types of plans, you'll be able to visit any doctor or

after the bell, amgen, electronic arts fireeye, linkedin, see them now. a.m. lauren simonetti, sandra smith and my. stuart: the british singer jane birkin, asked a the luxury goods company hermes to take her name offer bag. people for ethical treatment of animals alerting her to cruel slaughtering practice. >> these bags go 300 to $3,000. peta showed video of killing crocodiles and skins sent to hermes. they were stunned, not killed not cut but shot dead. the she said way animals are slaughtered. take my name off your bag. this is a lot of money. hermes. stuart: 300,000 for a bag. >> they go to 300 grand for a purse yeah. stuart: $300,000? >> yeah. stuart: are you kidding me? >> nope, not at all. stuart: hermes stock is unchanged. >> look i'm not in that camp but there are women that will pay this kind of money, upper side of manhattan don't live, don't know but they will to for it. she said look this is inhumane. stop it. stuart: i would have used example of upper west side full of limousine liberals. what do i know. you live there. >> yeah, i do. i do.